ALXP
ALMKT
Market cap32mUSD
Oct 21, Last price
1.04EUR
Name
Mauna Kea Technologies SAS
Chart & Performance
Profile
Mauna Kea Technologies SA develops and markets medical devices in Europe, the Middle East, Africa, the United States, Latin America, and Asia. The company designs, develops, and markets tools to visualize and detect cell abnormalities in real time during standard gastrointestinal and pulmonary endoscopy procedures. Its flagship product is Cellvizio, a confocal miniprobe endomicroscopy system which provides physicians and researchers high-resolution images of tissues at the cellular level. The company was incorporated in 2000 and is headquartered in Paris, France.
Valuation
Title EUR in thousands, except ratios and share amounts | FY |
---|---|
2023‑12 | |
Income | |
Revenues | 11,027 |
Cost of revenue | 10,158 |
Unusual Expense (Income) | |
NOPBT | 869 |
NOPBT Margin | 7.88% |
Operating Taxes | 475 |
Tax Rate | 54.66% |
NOPAT | 394 |
Net income | (3,727) |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | 7,394 |
BB yield | |
Debt | |
Debt current | 16,371 |
Long-term debt | 13,932 |
Deferred revenue | |
Other long-term liabilities | 72 |
Net debt | 17,115 |
Cash flow | |
Cash from operating activities | (753) |
CAPEX | (382) |
Cash from investing activities | (354) |
Cash from financing activities | 5,959 |
FCF | |
Balance | |
Cash | 8,005 |
Long term investments | 5,183 |
Excess cash | 12,637 |
Stockholders' equity | (24,877) |
Invested Capital | 37,445 |
ROIC | 1.05% |
ROCE | 6.91% |
EV | |
Common stock shares outstanding | 24,651 |
Price | |
Market cap | |
EV | |
EBITDA | 2,391 |
EV/EBITDA | |
Interest | 270 |
Interest/NOPBT | 31.07% |